Norwood, MA DPS, the global engineering group and its U.S. architectural partner TRIA has won a major contract to provide architectural, engineering and project management services for a new $110 million, 200,000 s/f GMP mRNA clinical manufacturing facility for biotechnology company, Moderna Therapeutics. 

DPS is providing full architectural and engineering design for the facility and also providing construction management oversight, commissioning, qualification and validation and procurement services. TRIA is designing clinical labs, offices, employee facilities and a conference center. Construction began  in October 2016 and be completed in early 2018.

DPS CEO Frank Keogh said, “This is a significant contract win for DPS and builds on the strong relationship we have developed with Moderna. We are proud to be supporting Moderna with this major investment in Norwood. This project demonstrates DPS’s ability to bid for and win large-scale capital investment design projects in the US.”

Moderna Therapeutics is a clinical stage biotechnology company pioneering messenger RNA Therapeutics to create a new generation of transformative medicines for patients. The company’s facility will enable the manufacture, quality, control and supply of clinical grade mRNA therapies and vaccines for Good Laboratory Practices toxicology studies as well as Phase 1 and Phase 2 clinical studies.

Moderna will carry out all manufacturing activities at the site—from raw material production to active pharmaceutical ingredients (APIs), formulation, filling and finish.